Krueger T - Search Results

1

Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.

Kosoff D, Krueger T, Lang JM. Kosoff D, et al. Among authors: krueger t. Immunotherapy. 2013 Nov;5(11):1243-54. doi: 10.2217/imt.13.116. Immunotherapy. 2013. PMID: 24188678 Review.

2

Augmenting antitumor immune responses with epigenetic modifying agents.

Héninger E, Krueger TE, Lang JM. Héninger E, et al. Front Immunol. 2015 Feb 4;6:29. doi: 10.3389/fimmu.2015.00029. eCollection 2015. Front Immunol. 2015. PMID: 25699047 Free PMC article. Review.

3

Inducible expression of cancer-testis antigens in human prostate cancer.

Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM. Heninger E, et al. Oncotarget. 2016 Dec 20;7(51):84359-84374. doi: 10.18632/oncotarget.12711. Oncotarget. 2016. PMID: 27769045 Free PMC article.

4

Reversible epigenetic alterations regulate class I HLA loss in prostate cancer.

Rodems TS, Heninger E, Stahlfeld CN, Gilsdorf CS, Carlson KN, Kircher MR, Singh A, Krueger TEG, Beebe DJ, Jarrard DF, McNeel DG, Haffner MC, Lang JM. Rodems TS, et al. Commun Biol. 2022 Sep 1;5(1):897. doi: 10.1038/s42003-022-03843-6. Commun Biol. 2022. PMID: 36050516 Free PMC article.

5

SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples.

Rodems TS, Juang DS, Stahlfeld CN, Gilsdorf CS, Krueger TEG, Heninger E, Zhao SG, Sperger JM, Beebe DJ, Haffner MC, Lang JM. Rodems TS, et al. Clin Epigenetics. 2022 Mar 10;14(1):37. doi: 10.1186/s13148-022-01252-4. Clin Epigenetics. 2022. PMID: 35272673 Free PMC article.

6

Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Brennen WN, J Thorek DL, Jiang W, Krueger TE, Antony L, Denmeade SR, Isaacs JT. Brennen WN, et al. Among authors: krueger te. Immunotherapy. 2021 Feb;13(2):155-175. doi: 10.2217/imt-2020-0066. Epub 2020 Nov 5. Immunotherapy. 2021. PMID: 33148078 Free PMC article.

7

Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN. Krueger TE, et al. Prostate. 2019 Feb;79(3):320-330. doi: 10.1002/pros.23738. Epub 2018 Nov 28. Prostate. 2019. PMID: 30488530 Free PMC article.

8

Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise.

Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Krueger TEG, et al. Stem Cells Transl Med. 2018 Sep;7(9):651-663. doi: 10.1002/sctm.18-0024. Epub 2018 Aug 1. Stem Cells Transl Med. 2018. PMID: 30070053 Free PMC article. Review.

9

Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype.

de Groot AE, Myers KV, Krueger TEG, Brennen WN, Amend SR, Pienta KJ. de Groot AE, et al. Neoplasia. 2022 Oct;32:100830. doi: 10.1016/j.neo.2022.100830. Epub 2022 Aug 5. Neoplasia. 2022. PMID: 35939881 Free PMC article.

10

Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.

de Groot AE, Myers KV, Krueger TEG, Kiemen AL, Nagy NH, Brame A, Torres VE, Zhang Z, Trabzonlu L, Brennen WN, Wirtz D, De Marzo AM, Amend SR, Pienta KJ. de Groot AE, et al. Prostate. 2021 Jul;81(10):629-647. doi: 10.1002/pros.24139. Epub 2021 May 5. Prostate. 2021. PMID: 33949714 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page